Bevacizumab and cancer treatment-related mortality

JAMA. 2011 Jun 8;305(22):2292; author reply 2292-3. doi: 10.1001/jama.2011.758.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Meta-Analysis as Topic
  • Mortality
  • Neoplasms / drug therapy*
  • Patient Care / standards
  • Randomized Controlled Trials as Topic

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab